Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Disease activity and the course of wrist joint deterioration over 10 years in the patients with early rheumatoid arthritis
Modern Rheumatology, 09/05/08
Toyohara I et al. - In patients with RA, it was noted that the deterioration of the wrist joint was influenced by disease activity. Identifying this activity and the course of wrist progression may be useful in predicting wrist deterioration.
Methods- Study to evaluate the course of radiographic deterioration of the wrist joint with RA
- Influence of disease activity on its deterioration was also monitored
- 122 wrists in 66 pts, who started treatment using DMARDs within the first year of the disease and followed for >10 yrs w/o surgical intervention
- Disease activity was high during the first 2 yrs, followed by a decrease and a flattening of the curve
- Generally, carpal collapse progressed more in the early stage and decreased linearly over 10 yrs
- Individually, continuous high disease activity and progression in radiographic damage were observed in carpal collapsed groups from early stage of the disease
- The cut-off values of the mean DAS28-CRP(3) during year 0–2, at yr 10 were 3.34 and 3.63 respectively
| Previous Article | Next Article |
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Denosumab update
Current Opinion in Rheumatology, 06/11/09
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
The Lancet - Early Online Publication, 07/01/09
Masitinib in the treatment of active rheumatoid arthritis: Results of a multicentre, open-label, dose-ranging, phase 2a study
Arthritis Research & Therapy, 06/25/09
Sponsor
Article Search
Sponsor


See Latest Articles


